Using our proprietary platform that combines AI-driven protein engineering and wet-lab directed evolution, we design therapeutic peptides with unprecedented potency and selectivity.
VRG Therapeutics is a leader in pharma R&D with world-class AI-driven drug discovery platform that combines in silico and wetlab capabilities to create miniproteins with extreme selectivity and outstanding affinity
Our mission is to cure diseases via targets and mechanism of actions (MoAs) that cannot be reached with traditional approaches.
Using our unique ISEPTM and CREATeTM technologies, we optimize peptides and proteins of artificial and natural origin using directed evolution to create peptide-based pharmaceuticals or cutting-edge cell and gene therapy (CGT) products. The directed evolution platforms provide the very essence of our peptide/protein-based projects and enable us to handle a diverse portfolio, hence ensure the long-term stability of our R&D activities. Whereas on the fundamentally different parts of our projects, we cooperate with companies or academic laboratories having outstanding expertise on the subject.
Benefits
why do we work with miniproteins?
Miniproteins combine the benefits of small molecules and large biologics. Ideal next-generation peptide therapeutic for targets intractable by antibodies and small molecules.
Stability
Stabilized by disulfide bonds
Resistant to protease degradation, hydrolysis and oxidation
Developability
Precisely tunable PK/PD via modular fusions or sustained-release formulation
Low-cost, versatile manufacturing options: synthetic and recombinant
Efficacy
Outstanding (subnanomolar) affinity
Excellent tissue penetration due to small size (max 60 amino acids)
Safety
Extreme, up to 10.000x selectivitydue to large interaction surface
No harmful breakdown products
Low immunogenicity
No formation of anti-drug antibodies (ADAs) due to small size, and protease resistance
Our Platform
ai-powered miniprotein platform
Our miniprotein based drug discovery platform uses two proprietary technologies leveraging AI-driven scaffold selection combined with state-of-the-art wet lab screening ensuring exceptional selectivity towards any drug target in a lightning-fast discovery process.
Hit validation in 6 months
Streamlined discovery and optimization procedure
AI-powered de novo scaffold selection for any target
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
